Results 101 to 110 of about 227,711 (241)

Evidence of blood–brain barrier dysfunction and CSF immunoglobulin synthesis in Down Syndrome Regression Disorder

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objectives This study sought to evaluate proteomic, metabolomic, and immune signatures in the cerebrospinal fluid of individuals with Down Syndrome Regression Disorder (DSRD). Methods A prospective case–control study comparing proteomic, metabolomic, and immune profiles in individuals with DSRD was performed.
Jonathan D. Santoro   +12 more
wiley   +1 more source

Clustering and Mining Accented Speech for Inclusive and Fair Speech Recognition [PDF]

open access: yesarXiv
Modern automatic speech recognition (ASR) systems are typically trained on more than tens of thousands hours of speech data, which is one of the main factors for their great success. However, the distribution of such data is typically biased towards common accents or typical speech patterns.
arxiv  

An MRI assessment of mechanisms underlying lesion growth and shrinkage in multiple sclerosis

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
By applying the tensor model, we analysed lesion orientation and the directionality of lesion expansion/contraction in multiple sclerosis. Each lesion is summarized as an ellipsoid, and the tensor model is applied to calculate lesion anisotropy. From the top to the bottom white matter atlas, surface‐in gradient segmentation and venous atlas used in the
Ermelinda De Meo   +9 more
wiley   +1 more source

If it does not help, it might hurt: Pharmacodynamics of a second IVIg course in Guillain–Barré syndrome

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
Abstract Objectives Intravenous immunoglobulin (IVIg) is an effective treatment for Guillain–Barré syndrome (GBS), but recovery varies between patients. This study aims to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of a single and a second IVIg dose (SID) in patients with GBS.
Sander J. van Tilburg   +7 more
wiley   +1 more source

Amygdala Neurodegeneration: A Key Driver of Visual Dysfunction in Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Visual disability in Parkinson's disease (PD) is not fully explained by retinal neurodegeneration. We aimed to delineate the brain substrate of visual dysfunction in PD and its association with retinal thickness. Methods Forty‐two PD patients and 29 controls underwent 3‐Tesla MRI, retinal spectral‐domain optical coherence tomography,
Asier Erramuzpe   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy